Daily Mirror – Coronavirus: Inside UK clinic where volunteers get paid up to £4,000 to be infected in race to find vaccine
by Rhian Lubin EXCLUSIVE: Infecting volunteers so they can be tested could help stop the spread of Covid-19 – so now 24 triallists face 14 days of solitary confinement and we took a look inside. As I lie in a hospital bed in a sterile clinic room, a nurse in blue scrubs with a full […]
BRR Media – Cathal Friel & hVIVO Chief Scientist Andrew Catchpole discuss the Coronavirus Challenge Study and the FLU-V Vaccine
Cathal Friel & hVIVO Chief Scientist Andrew Catchpole discuss recent developments and the Coronavirus Challenge Study and the FLU-V Vaccine with the BRR Media team.
Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study
Open Orphan PLC‘s (LON:ORPH) Cathal Friel and its subsidiary hVIVO’s chief scientist Dr Andrew Catchpole sat down with Proactive London’s Andrew Scott. This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they’re jointly developing have been published in a peer-reviewed journal. The data from the FLU-v 003 […]
Open Orphan #ORPH – Publication of Positive Results in Journal
Positive results from Phase IIb field study of FLU-v vaccine (FLU-v 003), which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group. FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate and the results have now been published in a peer review journal The publication in the Annals […]
Open Orphan #ORPH – Development of the World’s First Human Coronavirus Challenge Study Model
Open Orphan, the rapidly growing specialist Clinical Research Organisation (“CRO”) pharmaceutical services company whose London-based subsidiary hVIVO is the world leader in the provision of virology and vaccine challenge study services, is pleased to announce that it has commenced the development of the world’s first commercial human coronavirus challenge study model, also known as a Controlled […]
Irish Times – Open Orphan seals deal that could net more than €11.6m
by Colin Gleeson Dublin-listed pharma group announces contract with European biotech company Dublin-listed pharma services company Open Orphan has announced the signing of a new contract with a European biotech company that could yield it more than £10 million in revenue this year. Open Orphan, a European-focussed, rare and orphan drug consulting services platform, informed the Irish […]
Open Orphan #ORPH – New hVIVO contract signed with a European Biotech Company to provide RSV human challenge study
6 March 2020: Open Orphan plc (ORPH) the rapidly growing CRO specialist pharmaceutical services Group which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce the signing of a new contract with a European Biotech Company for the provision of a RSV human […]
Shares Magazine Spotlight – Open Orphan lining up for coronavirus fight
Open Orphan #ORPH – Appointment of new Director
Open Orphan , the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services , is pleased to announce, further to its announcement of 13 February 2020, the appointment to the board of Leo Toole as Chief Financial […]
Built to sell – can dealmaker Cathal Friel build (and sell) a £80m company in two years?
by Sean Keyes | Financial Correspondant Serial dealmaker Cathal Friel has an audacious plan: build and sell a pharma services company in two years. It could fetch as much as £100 million. What exactly is his plan? And will it work? On the cover of the fifth edition of Dr John Oxford’s book Human Virology […]